Analysts expect Aptinyx Inc (NASDAQ:APTX) to post earnings of ($0.48) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Aptinyx’s earnings. The business is scheduled to announce its next quarterly earnings results on Tuesday, November 13th.

According to Zacks, analysts expect that Aptinyx will report full-year earnings of ($2.24) per share for the current financial year, with EPS estimates ranging from ($2.68) to ($1.80). For the next financial year, analysts expect that the firm will post earnings of ($2.51) per share, with EPS estimates ranging from ($2.64) to ($2.37). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Aptinyx.

Aptinyx (NASDAQ:APTX) last released its earnings results on Tuesday, August 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($1.35). The firm had revenue of $2.13 million during the quarter, compared to the consensus estimate of $2.10 million.

A number of research firms have recently issued reports on APTX. Cowen began coverage on Aptinyx in a report on Monday, July 16th. They issued an “outperform” rating for the company. BMO Capital Markets began coverage on Aptinyx in a report on Monday, July 16th. They issued an “outperform” rating and a $32.00 target price for the company. JPMorgan Chase & Co. began coverage on Aptinyx in a report on Monday, July 16th. They issued an “overweight” rating and a $30.00 target price for the company. Finally, Leerink Swann began coverage on Aptinyx in a report on Monday, July 16th. They issued an “outperform” rating and a $35.00 target price for the company.

In other news, Director Adam Koppel acquired 400,000 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $6,400,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Norbert G. Riedel acquired 2,400 shares of the business’s stock in a transaction that occurred on Monday, June 25th. The shares were purchased at an average price of $16.00 per share, with a total value of $38,400.00. The disclosure for this purchase can be found here. Insiders bought 566,900 shares of company stock valued at $9,070,400 in the last 90 days.

Several large investors have recently made changes to their positions in APTX. Point72 Hong Kong Ltd purchased a new stake in shares of Aptinyx during the second quarter worth $134,000. Birchview Capital LP purchased a new stake in shares of Aptinyx during the second quarter worth $242,000. TD Asset Management Inc. purchased a new stake in shares of Aptinyx during the second quarter worth $253,000. Mutual of America Capital Management LLC purchased a new stake in shares of Aptinyx during the second quarter worth $457,000. Finally, Cowen Inc. purchased a new stake in shares of Aptinyx during the second quarter worth $546,000. Institutional investors and hedge funds own 60.05% of the company’s stock.

APTX opened at $28.00 on Wednesday. Aptinyx has a 12-month low of $17.35 and a 12-month high of $30.25.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Further Reading: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.